Adult Dosing

Active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7 vaccine

• 1 tab PO of adenovirus type 4 and one tab of adenovirus type 7

Pediatric Dosing

• Safety and efficacy have not been established in patients < 17 years of age

[Outline]

• Adult Dosing
• Pediatric Dosing

• Active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7 vaccine

• Hypersensitivity to any of the ingredients of the product
• Pregnant women
• Severe allergic reaction such as anaphylaxis to any ingredient
• Inability to swallow

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Safety and efficacy has not been evaluated in patients with altered immunocompetence
• Contains live viruses that are shed in the stool and can cause disease if transmitted
• People who come in close contact with those who were vaccinated, including other vaccinees, may be exposed to the virus present in the stool and may develop disease
• Persons vaccinated with adenovirus type 4 and type 7 vaccine, live, oral should be cautious when in close contact with children < 7 years of age and immunocompromised patients such as patients having HIV or cancer, or patients receiving immunosuppresive therapy
• Tablets contain human albumin (< 0.3 mg/tablet), hence it carries a remote risk for transmission of viral diseases

Pregnancy Category:X; use is contraindicated

Breastfeeding: The Centers for Disease Control and Prevention states that vaccines given to a nursing mother does not affect breastfed infants and breastfeeding is not a contraindication to influenza vaccine. This information is based upon LactMed database (available at

• CNS: Headache, pyrexia
• RESP: Nasal congestion, pharyngolaryngeal pain, cough, upper respiratory tract infection
• GI: Nausea, diarrhea, abdominal pain upper, vomiting
• MUSC: Arthralgia

• Live oral vaccine; replicates in intestinal tract and induces immunity in persons with low or no pre-existing neutralizing antibodies to adenoviruses types 4 and 7
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Only generic available

US Availability

adenovirus type 4 and type 7 vaccine, live oral

• 1 adenovirus type 4 tablet and 1 adenovirus type 7 tablet

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Immunologic

Vaccines

Viral